The data underlying the results presented in the study are available from VigiBase, the single largest drug safety data repository in the world, for researchers who meet the criteria for access to confidential data via the following address: <Vigibase@who-umc.org>

Introduction {#sec005}
============

Drugs like Praziquantel have been widely used for Soil-Transmitted helminthiasis and schistosomiasis control as those infections are burdensome to school-aged children in many parts of the world \[[@pntd.0008198.ref001]\]. Praziquantel, a broad spectrum anthelmintic with activity against trematode or cestode helminthic infections of human and veterinary origin, has been in use since 1980 \[[@pntd.0008198.ref002]\]. The dose of praziquantel in Mass Drug Administration (MDA) continues to be calculated based on the height of the recipient in reference to the WHO dose pole \[[@pntd.0008198.ref003],[@pntd.0008198.ref004]\] in many countries around the world including Eritrea. Studies from some African countries however demonstrate marked inaccuracies in the WHO dosing recommendations and suggest adopting their own pole \[[@pntd.0008198.ref005],[@pntd.0008198.ref006],[@pntd.0008198.ref007]\].

The Eritrean Pharmacovigilance Center has been working relentlessly to integrate its activities in various public health programs. One of these is the Neglected Tropical Diseases (NTD) control program. As a result of the collaboration between the Eritrean Pharmacovigilance Center and NTD control program, stimulated passive surveillance activities in Mass Drug Campaigns were partially implemented in 2017. The outcome was a surge of reports of adverse events related primarily to Praziquantel use in MDA. In September 2019, there were close to 2600 reports of Praziquantel related adverse events in the WHO global individual case safety reports (ICSRs) database, VigiBase \[[@pntd.0008198.ref008]\] submitted from Eritrea. These represents close to 65% of the globally reported cases to this drug. The reactions comprised largely various gastrointestinal disorders as nausea and vomiting and other systemic events.

Of note were the 61 cases of visual abnormalities namely blurred vision and visual impairments observed in several cases most of which were received in 2017. The product information of Biltricide (praziquantel 600mg tablets) does not mention visual problems in the adverse effects section of the document \[[@pntd.0008198.ref009]\] nor does other references except for post-marketing surveillance reports of visual disturbance in one drug information website \[[@pntd.0008198.ref010]\]. This work is therefore to assess the causal relationship of visual abnormalities and Praziquantel.

Methods {#sec006}
=======

On September 28, 2019, data was retrieved from VigiBase, the WHO international ICSRs database developed and maintained by the Uppsala Monitoring Center (UMC), Sweden, via VigiLyze; an analysis tool also developed and maintained by the UMC.

First, search was made to identify all praziquantel related adverse events by setting 'Praziquantel' as drug substance and 'all adverse events' as reactions term. This provided us reports of praziquantel related adverse events at global and country level. As the aim of the study was to the assess causal relationship of praziquantel and visual disorders, the search was further narrowed down by applying 'Eritrea' as country, 'praziquantel' as drug substance and 'eye disorders' (system organ class), as reaction term. The retrieved dataset was then exported into Excel spreadsheet for descriptive analysis (mean, median and frequency measures). Causality assessment in case series was done using Austin Bradford-Hill criteria \[[@pntd.0008198.ref011]\] by evaluating the available information on the association of praziquantel with blurred vision against the nine criteria namely the association's strength, temporality, specificity, consistency, biological plausibility, dose response relationship, experimental evidence, available analogies and coherence with established science.

In all ICSRs retrieved from VigiBase, the identities of individual cases are anonymous, thus; individual level information is held confidential.

Results {#sec007}
=======

A total of 3968 adverse events related to praziquantel, submitted from different countries, were retrieved from the WHO global ICSRs database. Of these adverse events, 65% (n = 2579), from which sixty-one cases of visual abnormalities associated with praziquantel namely blurred vision (47), visual impairment (13) and lacrimation increased (1) were retrieved, were submitted by Eritrea. ([Fig 1](#pntd.0008198.g001){ref-type="fig"}).

![Summary results of Praziquantel related cases of visual abnormalities submitted from Eritrea to the WHO global individual case safety reports database.](pntd.0008198.g001){#pntd.0008198.g001}

All the 61 cases were reported in the time period between January 2017 and August 2019. The reports came with a mean completeness score of 0.85 in the scale of 0 to 1. The Information Component (IC~025~) generated by the database for the reaction terms blurred vision and visual impairment was +0.82 and -1.01 respectively.

The age of the recipient was reported in all but one case and the median age was found to be 33 years (range 10--72). Cases comprised a similar sex distribution with more females (35/61) than males. The time to reaction onset as reported in the 61 cases lies within the same day of administration of the drug.

Praziquantel was the only suspected drug in 47 of the 61 cases, in the rest 13 cases Mebendazole was co-reported (as a co-suspect in seven and concomitant in six cases) while in the remaining one case, Albendazole was a co-suspect. In 28 of the 61 cases blurred vision (26) and visual impairment (2) were the sole reported reactions. The remaining 33 cases reported additional reactions including GI-disorders, dizziness, headache and other systemic side effects. The dosing variation ranged from 1 tablet (600mg) to 4 tablets (2400mg) of praziquantel while the dose of Menbendazole was 500mg in all the 13 cases in which the drug is co-reported. [Table 1](#pntd.0008198.t001){ref-type="table"} below summarizes some key variables of each of the 61 cases retrieved. Praziquantel was administered as a single dose only in all the cases for prophylaxis in MDA and thus, information on de-challenge and re-challenge were unobtainable. All the 61 events were reported to have been resolved spontaneously soon after the onset.

10.1371/journal.pntd.0008198.t001

###### Summary of selected variables for the 61 cases of visual abnormalities related to praziquantel (PZQ).

![](pntd.0008198.t001){#pntd.0008198.t001g}

  Case No.   Sex      Age (Y)   Co-reported Drugs: Suspect (S) or Concomitant(C)   PZQ Dose   Reaction(s)
  ---------- -------- --------- -------------------------------------------------- ---------- --------------------------------------------------------
  1          Male     \-        Mebendazole (S)                                    1200 mg    Vision blurred
  2          Male     10        Mebendazole (S)                                    1200 mg    Vision blurred
  3          Female   11        None                                               1500 mg    Vision blurred
  4          Female   11        None                                               1200 mg    Visual impairment, nausea and headache
  5          Male     12        None                                               1200 mg    Visual impairment and GI-disorder
  6          Male     12        None                                               1200 mg    Vision blurred
  7          Female   12        Mebendazole (S)                                    1500 mg    Vision blurred
  8          Female   13        None                                               1500 mg    Vision blurred
  9          Male     14        Mebendazole (C)                                    1500 mg    Vision blurred and headache
  10         Male     14        None                                               2400 mg    Vision blurred
  11         Male     14        None                                               1200 mg    Visual impairment, headache and GI-disorder
  12         Male     14        Mebendazole (S)                                    1200 mg    Vision blurred
  13         Male     15        Mebendazole (S)                                    2400 mg    Vision blurred, malaise and balance disorder
  14         Male     15        None                                               1200 mg    Vision blurred
  15         Female   15        Mebendazole (C)                                    \-         Vision blurred, nausea, dizziness and asthenia
  16         Female   15        None                                               1800 mg    Vision blurred
  17         Male     17        None                                               2400 mg    Visual impairment
  18         Female   18        None                                               1800 mg    Vision blurred
  19         Female   19        None                                               1800 mg    Visual impairment, headache and dyspepsia
  20         Female   19        None                                               2400 mg    Vision blurred, dizziness and abdominal pain
  21         Female   19        None                                               2400 mg    Vision blurred
  22         Female   19        None                                               1800 mg    Vision blurred
  23         Female   20        Mebendazole (S)                                    1200 mg    Vision blurred and vomiting
  24         Female   20        None                                               1500 mg    Vision blurred
  25         Female   22        None                                               2400 mg    Visual impairment, headache and GI-disorder
  26         Female   25        Albendazole (S)                                    1500 mg    Visual impairment, vomiting and vertigo
  27         Male     25        None                                               1800 mg    Vision blurred
  28         Female   27        None                                               1800 mg    Vision blurred
  29         Male     28        None                                               2400 mg    Visual impairment
  30         Male     32        None                                               1800 mg    Vision blurred
  31         Female   33        None                                               2400 mg    Vision blurred
  32         Female   33        None                                               2400 mg    Vision blurred
  33         Male     35        None                                               1800 mg    Vision blurred
  34         Female   38        Mebendazole (C)                                    600 mg     Lacrimation increased, headache, chest pain and nausea
  35         Female   38        None                                               1800 mg    Visual impairment, dyspepsia and GI-disorder
  36         Female   40        None                                               2400 mg    Visual impairment and vomiting
  37         Female   40        None                                               2400 mg    Vision blurred, abdominal pain and headache
  38         Female   40        None                                               1800 mg    Vision blurred
  39         Male     40        None                                               1800 mg    Vision blurred, dizziness and vomiting
  40         Female   45        Mebendazole (C)                                    \-         Vision blurred, nausea, asthenia and dizziness
  41         Female   45        None                                               1800 mg    Visual impairment, dyspepsia, nausea and headache
  42         Male     45        Mebendazole (C)                                    \-         Vision blurred, dizziness and headache
  43         Female   48        None                                               1800 mg    Vision blurred, dizziness and abdominal pain
  44         Female   48        None                                               2400 mg    Vision blurred
  45         Female   50        None                                               2400 mg    Vision blurred
  46         Male     50        None                                               2400 mg    Vision Blurred and dizziness
  47         Female   50        None                                               1800 mg    Vision blurred, dizziness and asthenia
  48         Male     50        None                                               2400 mg    Vision blurred
  49         Female   58        None                                               1800 mg    Vision blurred
  50         Male     60        None                                               2400 mg    Vision blurred
  51         Female   60        None                                               1800 mg    Visual impairment and GI-disorder
  52         Male     60        None                                               2400 mg    Vision blurred
  53         Female   60        Mebendazole (S)                                    \-         Vision blurred and headache
  54         Female   62        None                                               2400 mg    Vision blurred, dizziness and abdominal pain
  55         Male     63        Mebendazole (C)                                    \-         Vision blurred and headache
  56         Male     65        None                                               1800 mg    Vision blurred, asthenia and abdominal pain
  57         Male     65        None                                               2400 mg    Vision blurred, abdominal pain and vomiting
  58         Male     70        None                                               2400 mg    Vision blurred
  59         Female   70        None                                               2400 mg    Vision blurred and abdominal discomfort
  60         Male     71        None                                               2400 mg    Vision blurred and headache
  61         Female   72        None                                               2100 mg    Visual impairment and GI-disorder

Discussion {#sec008}
==========

The positive IC value of praziquantel and blurred vision in the WHO global ICSRs database indicates that visual abnormalities were commonly reported than expected; making the association strong. The association of Praziquantel and visual abnormalities has been consistently reported over a period of three years although about 80% of the reports were received in the first year alone. This difference may be attributed to variation in the surveillance initiatives and coverage of MDA over the three years. There was also consistency in time to reaction onset, that is, reactions observed within the first 24 hours following administration of praziquantel in all the cases and all reactions resolved shortly following the onset. The association was also specific as visual abnormalities were the only reported reaction terms following the sole administration of praziquantel in 47.5% of the cases. The occurrence of the reactions within the first 24 hours following the administration of praziquantel in all the cases suggests a plausible temporal association.

To the best of the authors knowledge, there were however no experimental evidences from pre-clinical or clinical trials that associate visual abnormalities with Praziquantel. Evidence suggesting specific dose-response relationship between Praziquantel and the visual abnormalities are lacking at the moment. The single dose administered to the cases ranges from 1--4 tablets (600mg - 2400mg) and it was determined by referring to the WHO height-based dose pole for Praziquantel \[[@pntd.0008198.ref003],[@pntd.0008198.ref004]\]. According to the data from the National Statistics Office of Eritrea, more than a half of the Eritrean adult population was found to be underweight in reference to the age for weight band records of various age groups (in the range 16 to 50 years) compared to the global age for weight band suggested by the WHO. In this regard, as mass drug administration of praziquantel uses height-based dosing in Eritrea, some patients might be exposed to overdose of praziquantel which might be a risk factor, among others, for the frequent reports of visual abnormalities. Inaccuracies in the WHO dose pole for dose calculation of Praziquantel were clearly demonstrated in some studies from countries in Sub-Saharan Africa \[[@pntd.0008198.ref005],[@pntd.0008198.ref006],[@pntd.0008198.ref007]\]. These studies recommend countries to customize the WHO dose pole in order to fit their population's situation.

The deployment of mass drug administration of Praziquantel and implementation of stimulated passive surveillance of adverse events in Eritrea led to increased incidences of reporting of various drug related adverse events. Thousands of complaints following the administration of Praziquantel in mass campaigns might have been reported to health professionals. It is only in recent years that such complaints were appropriately documented and reported to the Eritrean Pharmacovigilance Center. About 2600 reports dominated by the common gastrointestinal side effects may not demonstrate an alarming situation as a whole taking into account the multiple campaigns carried out and hundreds of thousands of doses given in the same time period. Yet, the observation of several cases with visual abnormalities that are unexpected is certainly alarming.

This study had several limitations. Although Mebendazole 500mg tablet is normally co-administered with praziquantel in MDA, praziquantel was consistently reported as solely administered in several cases. Thus, exposure status might not have been appropriately reported. Moreover, the data set used in this assessment comprises reports of passive surveillance; thus, due to lack of denominator information we cannot determine the incidence rate of visual abnormalities associated with praziquantel.

In conclusion, taking into account the strength of the association, its consistency and specificity and the plausible time to onset, there seems to be a suggestive causal relationship between praziquantel and visual abnormalities. Overdosing of praziquantel might be a factor to contribute to the frequent occurrence of unusual adverse effects. The authors, therefore, recommend further vigilance by healthcare professionals and strengthening the integration of Pharmacovigilance into the NTD control programs to capture similar cases in future campaigns, safeguard consumers and strengthen this safety signal. We also recommend studies to validate the WHO dose pole accuracy for the Eritrean population as overdose might be a risk factor for the occurrence of these adverse effects.

10.1371/journal.pntd.0008198.r001
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Dear Mr. Debesai:

Thank you very much for submitting your manuscript \"Praziquanel and Risk of Visual Disorders: Case Series Assessment\" (PNTD-D-19-01761) for review by PLOS Neglected Tropical Diseases. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important topic but identified some aspects of the manuscript that should be improved.

We therefore ask you to modify the manuscript according to the review recommendations before we can consider your manuscript for acceptance. Your revisions should address the specific points made by each reviewer.

In addition, when you are ready to resubmit, please be prepared to provide the following:

\(1\) A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

\(2\) Two versions of the manuscript: one with either highlights or tracked changes denoting where the text has been changed (uploaded as a \"Revised Article with Changes Highlighted\" file); the other a clean version (uploaded as the article file).

\(3\) If available, a striking still image (a new image if one is available or an existing one from within your manuscript). If your manuscript is accepted for publication, this image may be featured on our website. Images should ideally be high resolution, eye-catching, single panel images; where one is available, please use \'add file\' at the time of resubmission and select \'striking image\' as the file type.

Please provide a short caption, including credits, uploaded as a separate \"Other\" file. If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License at <http://journals.plos.org/plosntds/s/content-license> (NOTE: we cannot publish copyrighted images).

\(4\) Appropriate Figure Files

Please remove all name and figure \# text from your figure files upon submitting your revision. Please also take this time to check that your figures are of high resolution, which will improve both the editorial review process and help expedite your manuscript\'s publication should it be accepted. Please note that figures must have been originally created at 300dpi or higher. Do not manually increase the resolution of your files. For instructions on how to properly obtain high quality images, please review our Figure Guidelines, with examples at: <http://journals.plos.org/plosntds/s/figures>

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/> PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We hope to receive your revised manuscript by Mar 13 2020 11:59PM. If you anticipate any delay in its return, we ask that you let us know the expected resubmission date by replying to this email.

To submit your revised files, please log in to <https://www.editorialmanager.com/pntd/>

If you have any questions or concerns while you make these revisions, please let us know.

Sincerely,

Xiao-Nong Zhou

Associate Editor

PLOS Neglected Tropical Diseases

Hélène Carabin
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-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer \#1: Minor revision

Authors should provide a brief description of how the causality assessment was done using Austin Bradford Hills Criteria.
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Reviewer \#2: (No Response)
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**Results**

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer \#1: It will be interesting to show the dose distribution of praziquantel. More so, as cases of visual impairment may be dose related.

It will be necessary to provide data on the weight distribution of the recipients with visual impairment. This is important as the authors suggested that the underweight profile of the Eritrean population may have resulted in overdosing and a possible risk factor for the occurrence of visual impairment.
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-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?
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Dear Mr. Debesai,

Thank you very much for submitting your manuscript \"Praziquantel and Risk of Visual Disorders: Case Series Assessment\" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.  
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\[1\] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript. 

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

\[2\] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don\'t hesitate to contact us if you have any questions or comments.

Sincerely,

Xiao-Nong Zhou
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PLOS Neglected Tropical Diseases

Hélène Carabin

Deputy Editor
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Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, [https://pacev2.apexcovantage.com. PACE](https://pacev2.apexcovantage.com. PACE) helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Data Requirements:

Please note that, as a condition of publication, PLOS\' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.

Reproducibility:

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosntds/s/submission-guidelines#loc-materials-and-methods>
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Dear Mr. Debesai,

We are pleased to inform you that your manuscript \'Praziquantel and Risk of Visual Disorders: Case Series Assessment\' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch within two working days with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.
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Xiao-Nong Zhou
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Dear Mr. Debesai,

We are delighted to inform you that your manuscript, \"Praziquantel and Risk of Visual Disorders: Case Series Assessment,\" has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Serap Aksoy

Editor-in-Chief
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Editor-in-Chief
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